Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Related news for (ADPT)
- Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
- 24/7 Market News Snapshot 05 August, 2025 – Adaptive Biotechnologies Corporation Common Stock (NASDAQ:ADPT)
- Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
- Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
- Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
